lomustine has been researched along with Adverse Drug Event in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6." | 2.72 | MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. ( Broglia, C; Cavanna, L; Chisesi, T; Corazza, GR; Corbella, F; Federico, M; Gobbi, PG; Iannitto, E; La Sala, A; Levis, A; Molica, S; Pavone, V; Sacchi, S; Valentino, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Gobbi, PG | 1 |
| Broglia, C | 1 |
| Levis, A | 1 |
| La Sala, A | 1 |
| Valentino, F | 1 |
| Chisesi, T | 1 |
| Sacchi, S | 1 |
| Corbella, F | 1 |
| Cavanna, L | 1 |
| Iannitto, E | 1 |
| Pavone, V | 1 |
| Molica, S | 1 |
| Corazza, GR | 1 |
| Federico, M | 1 |
1 trial available for lomustine and Adverse Drug Event
| Article | Year |
|---|---|
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2006 |
3 other studies available for lomustine and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |